Results From an Italian Expanded Access Program on Cannabidiol Treatment in Highly Refractory Dravet Syndrome and Lennox–Gastaut Syndrome

Background: Purified cannabidiol (CBD) was administered to highly refractory patients with Dravet (DS) or Lennox–Gastaut (LGS) syndromes in an ongoing expanded access program (EAP). Herein, we report interim results on CBD safety and seizure outcomes in patients treated for a 12-month period.Materia...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Luigi Francesco Iannone, Gabriele Arena, Domenica Battaglia, Francesca Bisulli, Paolo Bonanni, Antonella Boni, Maria Paola Canevini, Gaetano Cantalupo, Elisabetta Cesaroni, Manuela Contin, Antonietta Coppola, Duccio Maria Cordelli, Giovanni Cricchiuti, Valentina De Giorgis, Maria Fulvia De Leva, Marta De Rinaldis, Giuseppe d'Orsi, Maurizio Elia, Carlo Andrea Galimberti, Alessandra Morano, Tiziana Granata, Renzo Guerrini, Monica A. M. Lodi, Angela La Neve, Francesca Marchese, Silvia Masnada, Roberto Michelucci, Margherita Nosadini, Nicola Pilolli, Dario Pruna, Francesca Ragona, Anna Rosati, Margherita Santucci, Alberto Spalice, Nicola Pietrafusa, Pasquale Striano, Elena Tartara, Laura Tassi, Amanda Papa, Claudio Zucca, Emilio Russo, Oriano Mecarelli, The CBD LICE Italy Study Group
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Frontiers Media S.A. 2021-05-01
coleção:	Frontiers in Neurology
Assuntos:	cannabidiol epilepsy Dravet syndrome lennox-gastaut syndrome expanded access program
Acesso em linha:	https://www.frontiersin.org/articles/10.3389/fneur.2021.673135/full
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!